NeOnc Technologies Signs MoU with Abu Dhabi DoH for Brain Cancer Research

Key Facts

1NeOnc Technologies signed an MoU with the Abu Dhabi Department of Health to cooperate on CNS therapeutics and oncology research.

2Two children in Abu Dhabi are currently receiving investigational NEO100 through NeOnc's Compassionate Care program.

NeOnc Technologies signed a Memorandum of Understanding (MoU) with the Abu Dhabi Department of Health to cooperate on CNS therapeutics and oncology research. GlobeNewswire reported that the collaboration focuses on enhancing clinical trial opportunities, scientific exchange, and specialist training within the Emirate. Currently, two children in Abu Dhabi are receiving the investigational NEO100 treatment through the company's Compassionate Care program.

NTHI closed at $2.77 on October 20, 2026, with the stock trading between a low of $2.75 and a high of $2.93 during that session. The partnership represents a strategic effort by the clinical-stage biotech firm to explore a potential regional presence in Abu Dhabi and advance its oncology research pipeline.